SecBot SecBot
PRESS-RELEASE ·Filed Apr 29, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Positive early data supports Telix's pipeline differentiation; monitor full efficacy results from OPTIMAL-PSMA and regulatory milestones for TLX597-Tx and TLX591-Tx (Phase 3 ProstACT Global).

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.00
T+0 close · Apr 29, 2026 · via day close
Latest settled
−9.27%
T+60 · $9.98
Vs SPY
−12.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 30 $11.00entry
  2. T+1 · 7mo ago +2.36%α +2.14% · $11.26
  3. T+5 · 6mo ago −3.09%α −4.82% · $10.66
  4. T+20 · 6mo ago −14.27%α −19.50% · $9.43
  5. T+60 · 4mo ago −9.27%α −12.38% · $9.98

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix announces positive dosimetry data from Phase 2 OPTIMAL-PSMA trial of TLX597-Tx in mCRPC, showing low salivary gland and kidney uptake enabling dose intensification. The company is initiating a Phase 2 study (OPTIMAL-E) in mHSPC, advancing its pipeline in earlier-stage prostate cancer.

Key Facts

  • TLX597-Tx dosimetry demonstrates reduced radiation to salivary glands and kidneys compared to existing PSMA RLTs.
  • Dose-intensification regimen (8.5 GBq per cycle) shows potential for higher tumor uptake and wider therapeutic window.
  • Phase 2 OPTIMAL-E trial initiated in metastatic hormone-sensitive prostate cancer (mHSPC).
  • Data presented at 2026 International Prostate Cancer Symposium (IPCS 2026).

Financial Impact

No financial figures disclosed; potential depends on future clinical success and regulatory approval.

Risk Factors

  • Clinical trial failure or safety issues in later stages.
  • Competition from other PSMA-targeted therapies (e.g., Pluvicto).
  • Regulatory approval uncertainty and commercialization challenges.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3284336

Track record

27 reports on TLX

Performance horizon

9 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (10h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 29, 2026